Exact 2 mg Active Assay
Each tablet contains Lorazepam IP 2 mg with strict active assay uniformity, rapid disintegration, and dissolution complying with Indian Pharmacopoeia standards.
LORZIN-2 is a moderate-to-high potency oral formulation containing Lorazepam IP 2 mg by Blessme, Dellwich Lifescience LLP. Specifically indicated for severe generalized anxiety disorder, acute panic crises, debilitating anxiety-induced insomnia, and pre-operative tranquilization, providing robust GABAergic limbic suppression through direct Phase II glucuronidation.

Comprehensive pharmaceutical specifications, active API monograph compliance, pharmacokinetic profiles, and 4x5x10 blister packaging details for LORZIN-2.
LORZIN-2 provides 2 mg Lorazepam per compressed tablet. Prescribed when higher anxiolytic potency is required to control severe panic episodes, intense autonomic agitation, or pre-procedural apprehension.
In-depth pharmacological evaluation of Lorazepam 2 mg tablets, marketed as LORZIN-2 by Blessme (Dellwich Lifescience LLP). Covers GABAergic receptor mechanisms, clinical advantages of direct glucuronidation, and pharmaceutical franchise availability across India.
LORZIN-2 is a moderate-to-high potency oral benzodiazepine tablet formulated with 2 mg of pure Lorazepam IP. Formulated for clinical situations requiring higher GABAergic inhibition than standard 1 mg doses can afford.
In patients experiencing severe panic disorder with agoraphobia or acute psychomotor agitation, LORZIN-2 delivers rapid calming of autonomic hyperarousal, terminating racing thoughts, hyperventilation, and terror.
Approved neurological and psychiatric indications for LORZIN-2 include:
Lorazepam 2 mg acts as a potent positive allosteric modulator at the GABAA receptor complex throughout the central nervous system.
By increasing the receptor’s affinity for gamma-aminobutyric acid (GABA), it facilitates the opening of ligand-gated chloride ion channels. The resulting cellular hyperpolarization suppresses excessive neuronal excitation in the amygdaloid complex, hippocampus, and cerebral cortex, delivering profound relief from psychic distress and muscular hypertonicity.
How clinicians choose between the dosage strengths:
LORZIN-2 must be taken strictly in accordance with medical advice:
LORZIN-2 contains Lorazepam, which carries potential for dependence and habit formation with prolonged therapy. Do not consume alcohol during therapy. Not recommended during pregnancy. Dispensed strictly against a valid registered medical prescription.
LORZIN-2 is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity, exact active content, and superior packaging stability.
Each tablet contains Lorazepam IP 2 mg with strict active assay uniformity, rapid disintegration, and dissolution complying with Indian Pharmacopoeia standards.
High-barrier blister packaging protects against ambient humidity and photodegradation, maintaining 36-month stability across all Indian climatic zones.
Every batch is verified through authenticated Certificates of Analysis (COA), HPLC active assay validation, and dissolution profiles adhering strictly to IP standards.
Produced in state-of-the-art cleanroom manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Prescribing guidance, contraindications, and drug interactions for Lorazepam 2 mg tablets.
LORZIN-2 is a Schedule H / Narcotic prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Approved neurological and psychiatric indications for LORZIN-2:
Key contraindications and monitoring requirements:
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including LORZIN-2 (Lorazepam Tablets IP 2 mg).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Whether you are seeking LORZIN-2 for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Secure district-level monopoly marketing rights for LORZIN-2 and the complete Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
When sourcing Lorazepam 2 mg tablets in India, LORZIN-2 by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
Manufactured in accredited facilities using IP grade active APIs, ensuring exact content uniformity and fast dissolution.
Tamper-evident, moisture-resistant blister strips protect tablets from ambient humidity and transport friction.
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Exclusive district-level franchise rights for LORZIN-2 and the Blessme portfolio with promotional visual aids.
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Lorazepam 2 mg tablets.
LORZIN-2 is an oral prescription tablet from the Blessme division of Dellwich Lifescience. It contains Lorazepam IP 2 mg, indicated for severe generalized anxiety, acute panic disorder, severe insomnia associated with anxiety, and pre-operative medication.
Lorazepam 2 mg enhances the action of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. This increases neuronal chloride conductance, calming acute neuronal hyper-excitation in the amygdala and cerebral cortex to extinguish intense panic and physical agitation.
LORZIN-2 contains 2 mg Lorazepam, making it suitable for patients experiencing severe panic crises, debilitating anxiety unresponsive to lower doses, acute agitation, or patients requiring significant pre-procedure sedation.
Lorazepam is absorbed quickly from the gastrointestinal tract, achieving peak blood levels within 1.5 to 2 hours. Acute anxiolysis and sedation are typically noticeable within 30 to 45 minutes of oral intake.
Lorazepam has an intermediate elimination half-life of approximately 10 to 20 hours. It is eliminated without the production of active metabolites, reducing residual hangover risks compared to long-acting benzodiazepines like Diazepam.
Yes. Due to the 2 mg strength, sedation and drowsiness are prominent effects. Patients must not drive vehicles or operate hazardous equipment while taking LORZIN-2.
No. Alcohol must never be consumed while taking Lorazepam. The combination produces synergistic central nervous system depression, potentially resulting in fatal respiratory failure or profound sedation.
Yes. Lorazepam 2 mg carries potential for physical and psychological dependence with extended therapy. It is generally prescribed for short courses (2 to 4 weeks) under direct clinical monitoring.
No. Abrupt cessation of Lorazepam 2 mg can cause severe withdrawal reactions, including intense rebound anxiety, tremors, insomnia, and in severe cases, seizures. A supervised step-down tapering protocol is required.
Lorazepam is contraindicated during pregnancy due to risks of congenital malformations, fetal CNS depression, and neonatal withdrawal syndrome.
LORZIN-2 is packaged in 4x5x10 blister strips (200 tablets per box) with tropicalized moisture-barrier foil to ensure optimal shelf life across diverse climatic zones in India.
Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.
Yes. Dellwich Lifescience provides turnkey contract manufacturing for Lorazepam oral solid dosage forms with WHO-GMP certification, validated analytical dossiers, and rapid batch dispatch.
Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with rapid nationwide logistics connections.
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Lorazepam 2 mg Tablets.